Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France.
Lombard-Bohas C, Mitry E, O'Toole D, Louvet C, Pillon D, Cadiot G, Borson-Chazot F, Aparicio T, Ducreux M, Lecomte T, Etienne PL, Cacheux W, Legoux JL, Seitz JF, Ruszniewski P, Chayvialle JA, Rougier P; FFCD-ANGH-GERCOR. Lombard-Bohas C, et al. Among authors: cadiot g. Neuroendocrinology. 2009;89(2):217-22. doi: 10.1159/000151562. Epub 2008 Aug 22. Neuroendocrinology. 2009. PMID: 18719344
Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S, Guimbaud R, Niccoli P, Legoux JL, Mitry E, Rohmer V, Ruszniewski P, Walter T, Ducreux M, Couvelard A, Scoazec JY, Ramond-Roquin A, Caroli-Bosc FX, Hentic O. Roquin G, et al. Among authors: cadiot g. Neuroendocrinology. 2018;106(1):38-46. doi: 10.1159/000457955. Epub 2017 Feb 3. Neuroendocrinology. 2018. PMID: 28152531
New treatment strategies in advanced neuroendocrine tumours.
Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G. Walter T, et al. Among authors: cadiot g. Dig Liver Dis. 2012 Feb;44(2):95-105. doi: 10.1016/j.dld.2011.08.022. Epub 2011 Oct 7. Dig Liver Dis. 2012. PMID: 21983252 Review.
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G, Dromain C, Farace F, Rougier P, Ducreux M. Mitry E, et al. Among authors: cadiot g. Eur J Cancer. 2014 Dec;50(18):3107-15. doi: 10.1016/j.ejca.2014.10.001. Epub 2014 Oct 18. Eur J Cancer. 2014. PMID: 25454413 Clinical Trial.
Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).
Manfredi S, Walter T, Baudin E, Coriat R, Ruszniewski P, Lecomte T, Laurenty AP, Goichot B, Rohmer V, Roquin G, Cojocarasu OZ, Lombard-Bohas C, Lepage C, Morcet J, Cadiot G. Manfredi S, et al. Among authors: cadiot g. Endocrine. 2017 Sep;57(3):504-511. doi: 10.1007/s12020-017-1355-9. Epub 2017 Jun 29. Endocrine. 2017. PMID: 28664309 Free article.
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
de Mestier L, Walter T, Brixi H, Evrard C, Legoux JL, de Boissieu P, Hentic O, Cros J, Hammel P, Tougeron D, Lombard-Bohas C, Rebours V, Ruszniewski P, Cadiot G. de Mestier L, et al. Among authors: cadiot g. Neuroendocrinology. 2019;108(4):343-353. doi: 10.1159/000498887. Epub 2019 Feb 13. Neuroendocrinology. 2019. PMID: 30759445
[What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?].
Legoux JL, Bedenne L, Seitz JF, Pezet D, Rougier P, Bouché O, Barbare JC, André T, Malka D, Cadiot G, Ruskoné-Foumestraux A, Landi B, Peiffert D, Ducreux M, Louvet C, Dorval E. Legoux JL, et al. Among authors: cadiot g. Gastroenterol Clin Biol. 2006 Oct;30(10):1191-5. doi: 10.1016/s0399-8320(06)73510-2. Gastroenterol Clin Biol. 2006. PMID: 17075477 Free article. French. No abstract available.
Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study.
Vezzosi D, Walter T, Laplanche A, Raoul JL, Dromain C, Ruszniewski P, d'Herbomez M, Guigay J, Mitry E, Cadiot G, Leboulleux S, Lombard-Bohas C, Borson-Chazot F, Ducreux M, Baudin E. Vezzosi D, et al. Among authors: cadiot g. Int J Biol Markers. 2011 Apr-Jun;26(2):94-101. doi: 10.5301/JBM.2011.8327. Int J Biol Markers. 2011. PMID: 21574156 Free article.
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T. Lepage C, et al. Among authors: cadiot g. Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11. Dig Liver Dis. 2017. PMID: 28292641 Clinical Trial.
287 results